The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorderNicolas Garel, MD; Kyle T. Greenway MD, MSc; Ridha Joober MD, PhDA 22-year-old man is starting out-patient follow-up for a first episode of psychosis (FEP) that started in the con-text of a severe cannabis use disorder. The patient initially required 3 months of hospitalization and was stabilized with paliperidone. He accepted being switched to the long-acting injectable form and was discharged on paliperi-done palmitate 150 mg, to be adminis-tered intramuscularly every 21 days.During his follow-up at the FEP pro-gram, the patient reported that he had resumed cannabis consumption after his discharge and experienced a recru-descence of his positive psychotic symptoms and paranoia. He men-tioned not having gone out in public for more than 2 weeks because he was under the impression that people were looking at him and reading his mind. The patient was referred to psycho-therapy for motivational interviewing regarding his substance use, but he did not present to his appointment and lacked motivation to engage in this type of intervention.